



GHIT R&D Forum 2024

Leap from Basics!
Rethinking the Needs
& Exploring
Innovative Solutions
for Neglected Diseases

Date: December 5th, 2024

Venue: Tokyo Garden Terrace

Kioi Conference (In-person sessions)

GHIT R&D Forum 2024

Program

Time	Program	
9:15	Registration	
9:45-9:50	Greetings and Opening Remarks	
9:50-10:05	Keynote Speech	
10:10-11:10	Session 1	Needs on TB — From innovation in health technologies to reaching the last mile —
11:20-12:20	Session 2	Linking NTD Innovations with Health Systems for Pandemic Preparedness
12:20 -13:20	Lunch Break	Proposal Writing Seminar/Q&A Session Booth Exhibition
13:20-14:20	Session 3	Needs on Malaria — Approaches to address geographic variations —
14:20-14:50	Networking Session	
14:50 -15:15	Coffee Break	Booth Exhibition
15:15-16:15	Session 4	Technologies on the Ground — Adapting new technologies in the context of LMICs —
16:25-17:25	Session 5	From R&D to Access and Delivery — Connecting for an end-to-end Ecosystem —
17:25-17:30	Closing Remarks	
17:30-18:30	Reception Party	

Opening Remarks & Closing Remarks



Dr. Hiroki Nakatani

Chair & Representative Director
GHIT Fund



Dr. Osamu Kunii

CEO & Executive Director
GHIT Fund

Speakers

Keynote Speech

People centered innovation: connecting the dots on innovation, access and delivery



Dr. Mandeep Dhaliwal


Director, HIV and Health Group, Bureau of Policy and Programme Support
United Nations Development Programme (UNDP)



Dr. Mandeep Dhaliwal is the Director of UNDP's HIV and Health Group, Bureau of Policy and Programme Support. She has over 25 years of experience working on HIV, health, human rights and evidence-based policy and programming in low and middle-income countries.

Dr. Dhaliwal joined UNDP in 2008 and was the architect of the Global Commission on HIV and the Law, as well as the UN Secretary General's High-Level Panel on Access to Medicines. Prior to joining UNDP, she was a senior adviser to the Dutch Royal Tropical Institute's Special Programme on HIV/AIDS. From 2000 to 2006, Dr. Dhaliwal worked for the International HIV/AIDS Alliance's Policy, Research and Good Practice Team in the United Kingdom, where she focused on issues of HIV care and treatment in developing countries. From 1993 to 2000, she worked on HIV and human rights in India, including as the founding coordinator of the Lawyers Collective HIV/AIDS Unit, a leading human rights organization, establishing the Unit's legal aid, public interest litigation, legal literacy and policy/advocacy work.

Floor map



Speakers

*For speaker's bio, please refer to the event webpage



Session 1:

Needs on TB — From innovation in health technologies to reaching the last mile —



Dr. Jacob Creswell

Head, Innovations and Grants
Stop TB Partnership



Dr. Nader Fotouhi

Chief Scientific Officer
TB Alliance



Mr. Hirotaka Michiba

Manager
FUJIFILM Corporation



Mr. Yuta Ohashi

Senior Associate
Toyota Tsusho Corporation



Dr. Elana Van Brakel

Medical Director
IAVI



Session 2:

Linking NTD Innovations with Health Systems for Pandemic Preparedness



Dr. Masahiro Kajihara

Associate Professor
International Institute for Zoonosis Control,
Hokkaido University



Dr. Charles Mowbray

Discovery Director
Drugs for Neglected Diseases initiative (DNDi)



Dr. Nobuo Saito

Associate Professor
Institute of Tropical Medicine, Nagaaki University



Dr. Aya Yajima [Video Presentation]

Regional Advisor - Neglected Tropical Diseases (NTDs)
WHO South-East Asia Region (SEARO)

Session 3:

Needs on Malaria — Approaches to address geographic variations —



Prof. Arjen Dondorp

Deputy Director and Head of Malaria & Critical Illness
Department
Mahidol-Oxford Tropical Medicine Research Unit (MORU)



Prof. Osamu Kaneko

Dean and Professor
Institute of Tropical Medicine, Nagasaki University



Prof. Eizo Takashima

Professor
Ehime University



Dr. Paul Willis

VP Head of Early Development
Medicines for Malaria Venture



Session 4:

Technologies on the Ground — Adapting new technologies in the context of LMICs —




Dr. Jeremy Burrows

VP Head of Research Drug Discovery
Medicines for Malaria Venture



Ms. Mariko Kitahama

Assistant Manager
NEC Corporation



Dr. Keita Wagatsuma

Assistant Professor
Division of International Health, Graduate School of Medical
and Dental Sciences, Niigata University



Dr. Peter Warner

Senior Program Officer
Bill & Melinda Gates Foundation



Session 5:

From R&D to Access and Delivery — Connecting for an end-to-end Ecosystem —



Dr. Ashley Birkett

Global Head, Bacterial & Parasitic Diseases
PATH




Dr. Timothy Endy

CEPI Program Leader for the Disease X Vaccine Library
and Chikungunya Vaccines
CEPI



Dr. Loice Kikwai

Regulatory Affairs Lead
MARKET ACCESS AFRICA



Dr. Oumar Ndiaye

R&D and Technology Transfer Specialist
Institut Pasteur de Dakar



Exhibition Information



Time : 10:00 - 18:30

Venue : Seminar Room C, D



FUJIFILM Toyama Chemical offers integrated drug discovery services for infectious disease. We have been engaged in small molecule drug discovery in infectious diseases for decades and has a proven track record of discovering important drugs for the treatment of infectious diseases. This is owing to our competitive advantage based on our strengths in drug discovery: insight, originality, and unconventional idea. Our drug discovery experts embody our track record and strengths can accelerate your drug discovery through our integrated drug discovery services.



Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to the research and development, production, and commercialization of biotherapeutics and vaccines to address life-threatening diseases. Gennova is transforming healthcare by creating efficient and effective solutions for manufacturing and successfully commercializing bio-therapeutics across cardiovascular, neurology, nephrology, ophthalmology, and oncology segments. Gennova has developed world's first thermostable self-amplifying mRNA-based platform technology for COVID-19 vaccines, including India's first mRNA vaccine, GEMCOVAC®-19. Gennova along with other partners in USA and Japan are engaged with GHIT for development of live attenuated vaccine for leishmaniasis and diagnostic leishmanin antigen skin test.



MMV is a Swiss-based not-for-profit organization working to deliver a portfolio of accessible medicines with the power to treat, prevent and eliminate malaria. Born in 1999, out of a need for greater health equity, we close critical gaps in research, development and access – working “end-to-end” to expand the use of existing antimalarials and innovate new compounds to protect public health. This starts with women and children.




Nanotis is a University of Tokyo affiliated start-up developing next-generation digital testing technologies covering a wide range of virus inspections including COVID-19 and flu. Nanotis successfully developed a technology called "Nucleic Acid Navigated Optically Traceable Immuno-Sensing (NANOTIS method)," which will achieve simple, quick and affordable saliva-based testing with excellent accuracy. With the NANOTIS method, test results will be digitally processed in a single step, and it has the potential to become a core technology for efficient infection control.



NEC is a global technology company that was founded in Japan over 120 years ago. Today, NEC has a broad portfolio of solutions from submarine cables to satellites, and from smart city infrastructure to world leading biometrics and AI. NEC co-creates solutions with UN and other international organizations, committed to "Digitalization for LEAVE NO ONE BEHIND." Showcasing cutting edge technologies and model cases in the field of Renewable Energy, Agriculture, Healthcare and AI, NEC aspires to create a more inclusive and sustainable future.



PHC Corporation is a global leader in healthcare and life sciences, offering advanced medical equipment, laboratory solutions, and diagnostics. Its flagship PATHFAST system provides rapid, precise point-of-care testing, including reagents for tuberculosis diagnosis. This innovation supports early detection and treatment, enhancing patient care. Serving hospitals, research institutions, and clinics worldwide, PHC is committed to advancing healthcare through cutting-edge technology and sustainable practices.



Remedy and Company Corporation is a Health Tech Platformer providing Clinical Research Support for clients across the globe. We are a member of GHIT and have aligned our objectives to further the 100 Days Mission on behalf of Japan and the APAC countries. We specialize in field work for the Global South which need further support for neglected tropical diseases (NTD), Malaria, Tuberculosis and AMR. As part of our innovative task force, we are pursuing to be the first clinical research center for Controlled Human Infection Models in Asia.

GHIT's Videos & Interviews of our Partners




"SDGs Talk" Global Health Discussion with Osamu Kunii - Vol. 2 -



"SDGs Talk" Global Health Discussion with Osamu Kunii - Vol. 1 - Ken Noguchi



Addressing Neglected Tropical Diseases: Insights from Academia



Addressing Neglected Tropical Diseases: Insights from the Private



Mother-to-Child Transmission of Chagas disease



Partnerships with Japanese Researchers



Combating



Combating Schistosomiasis in Tanzania



Innovative path for development of new pediatric treatment



Follow us!



Fight Neglected Diseases through Partnerships



Global Health Innovative Technology Fund